Fernández de Larrea, Carlos http://orcid.org/0000-0003-4930-9255
Kyle, Robert
Rosiñol, Laura http://orcid.org/0000-0002-2534-9239
Paiva, Bruno http://orcid.org/0000-0003-1977-3815
Engelhardt, Monika http://orcid.org/0000-0003-0405-1676
Usmani, Saad http://orcid.org/0000-0002-5484-8731
Caers, Jo http://orcid.org/0000-0002-3175-1195
Gonsalves, Wilson
Schjesvold, Fredrik http://orcid.org/0000-0003-1096-0569
Merlini, Giampaolo http://orcid.org/0000-0001-7680-3254
Lentzch, Suzanne http://orcid.org/0000-0003-1708-7344
Ocio, Enrique
Garderet, Laurent
Moreau, Philippe
Sonneveld, Pieter http://orcid.org/0000-0002-0808-2237
Badros, Ashraf
Gahrton, Gösta
Goldschmidt, Hartmut http://orcid.org/0000-0003-0961-0035
Tuchman, Sascha http://orcid.org/0000-0003-2109-1573
Einsele, Hermann http://orcid.org/0000-0002-7680-0819
Durie, Brian
Wirk, Baldeep http://orcid.org/0000-0002-2804-2531
Musto, Pellegrino
Hayden, Patrick
Kaiser, Martin http://orcid.org/0000-0002-3677-4804
Miguel, Jesús San http://orcid.org/0000-0002-9183-4857
Bladé, Joan
Rajkumar, S. Vincent http://orcid.org/0000-0002-5862-1833
Mateos, Maria Victoria http://orcid.org/0000-0003-2390-1218
Article History
Received: 18 August 2021
Revised: 10 November 2021
Accepted: 15 November 2021
First Online: 2 December 2021
Competing interests
: BP reports honoraria for lectures from and membership on advisory boards with Adaptive, Amgen, Bristol-Myers Squibb-Celgene, Creative BioLabs, Gilead, Janssen, Sanofi and Takeda; unrestricted grants from Celgene, EngMab, Roche, Sanofi, and Takeda; and consultancy for Bristol-Myers Squibb-Celgene, Janssen, Sanofi, and Takeda. LR reports honoraria from Janssen, BMS-Celgene, Amgen, Takeda, Sanofi, GSK. SZU reports grants and personal fees from Amgen, personal fees from Abbvie, grants from BMS, grants and personal fees from Celgene, personal fees from MundiPharma, grants from Pharmacyclics, grants and personal fees from Sanofi, grants and personal fees from Seattle Genetics, grants and personal fees from Janssen, grants and personal fees from Takeda, grants and personal fees from SkylineDX, grants and personal fees from Merck, grants and personal fees from GSK, outside the submitted work. FS reports honoraria from Abbvie, Amgen, BMS, Janssen, Novartis, Oncopeptides, Sanofi, Schain, SkyliteDX, Takeda; consultancy or advisory board from Celgene, Janssen, Oncopeptides, Sanofi, and unrestricted grants from Celgene, GSK, Janssen, Oncopeptides, Sanofi. SL reports honoraria or consultancy from Sorrento, Janssen, Celularity, Abbvie, GSK, Takeda, Karyopharm, Sanofi, Oncopetide and Caelum Biosciences; research grants from Karyopharm, Sanofi; and holds shares and serves on board of directors for Caelum Biosciences. EMO reports honoraria or consultancy funding from Janssen, BMS, Sanofi, GSK, Oncopeptides, Takeda, Pfizer and Amgen. LG reports consultancy or advisory boards from Takeda, Amgen, BMS/Celgene, and Janssen. GG reports honoraria or consultancy from Fujimoto Pharmaceutical Corporation, Japan. HG reports grants and/or provision of Investigational Medicinal Product from Amgen, BMS, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Sanofi; research grants from Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme (MSD), Sanofi, Mundipharma GmbH, Takeda, Novartis; and consultancy or advisory boards from Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda; and honoraria from Amgen, BMS, Celgene, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi. SAT reports grants received from Karyopharm, Sanofi Genzyme and Caelum; and honoraria from Karyopharm, Caelum, Sanofi Genzyme, Oncopeptides, and Shattuck Labs. HE reports honoria or consultancy and unrestricted grants from Janssen, BMS/Celgene, Amgen, Novartis, Takeda, Sanofi, GSK. BGMD reports consultancy or advisory boards from Takeda, Amgen, BMS/Celgene, and Janssen. MK reports consultancy from AbbVie, Amgen, BMS/Celgene, GSK, Janssen, Karyopharm, Seattle Genetics, Takeda; research funding from BMS/Celgene, Janssen; and educational or travel support from BMS/Celgene, Janssen, and Takeda. JSM reports consultancy or advisory boards from AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, MSD, Novartis, Roche, Sanofi, Takeda, SecuraBio, and Regeneron. MVM reports honoraria or consultancy from Janssen, BMS-Celgene, Takeda, Amgen, Abbvie, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Roche, Sea-Gen, Bluebird-bio. The remaining authors declare no competing interests.